CHI | Jotup

RAJANT NAMED 2024 “BEST PLACES TO WORK IN KENTUCKY” AND “TOP WORKPLACES” IN PHILADELPHIA FOR FOURTH CONSECUTIVE YEAR

Retrieved on:

星期二, 五月 14, 2024

Workplace, The Philadelphia Inquirer, Central Bank Center, Commonwealth, CHI, Culture, Commerce, Chamber of commerce, Kinetic, Comment, Family

The distinctions of being The Philadelphia Inquirer’s “Top Workplaces of 2024” and “Best Places to Work in Kentucky” were announced earlier this year.

Key Points:

The distinctions of being The Philadelphia Inquirer’s “Top Workplaces of 2024” and “Best Places to Work in Kentucky” were announced earlier this year.
The selection process is based on anonymous employee answers to survey questions centering on company policies, procedures, and culture.
It is their excellent work that feeds our success and global expansion year-over-year,” shares Rajant CEO and Co-founder Robert Schena.
Thank you to The Philadelphia Inquirer and the Kentucky Chamber of Commerce for the continued recognition.”

Barbie Celebrates Role-Model Athletes Who Have Broken Boundaries to Encourage Girls to Stay in Sports and Recognize Their Full Potential

Retrieved on:

星期三, 五月 22, 2024

View the full release here: https://www.businesswire.com/news/home/20240521496460/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20240521496460/en/
Barbie Celebrates Role-Model Athletes Who Have Broken Boundaries to Encourage Girls to Stay in Sports and Recognize Their Full Potential (Graphic: Business Wire)
Through initiatives like the Barbie Dream Gap Project , Barbie is committed to leveling the playing field for girls globally, in sports and beyond, to close the gap that comes between girls and their full potential.
The sports one-of-a-kind Role Model dolls serve as an embodiment of our shared values of passion, empowerment and individuality.
Girls in sports ages 12+ may sign up at https://voiceinsport.com/barbie to unlock the free mentoring with Barbie Role Models and educational content.
Featuring new drops each month, fans can purchase exclusive celebratory 65th anniversary items from UNO Canvas™ Barbie to apparel, accessories, and more.

Children's Hope India Honors Three Female Entrepreneurs At Its Annual Spring Luncheon

Retrieved on:

星期三, 五月 1, 2024

Corporation, Education, Twin, Woman, University of Oxford, Entrepreneurship, Lunch, Female, IDEX Corporation, CHI, SVP, MBA, Management

NEW YORK, May 1, 2024 /PRNewswire-PRWeb/ -- Nonprofit organization Children's Hope India (CHI) has announced the honorees for this year's Spring Luncheon which will be held on Wednesday, May 8th at Leonard's Palazzo in New York. The luncheon will benefit CHI's "30/30 Education Initiative" which provides early education, tuition, concept learning and career counseling to children attending CHI centers.

Key Points:

The luncheon will benefit CHI's "30/30 Education Initiative" which provides early education, tuition, concept learning and career counseling to children attending CHI centers.
This year's Woman of Distinction is Roopa Unnikrishnan, who is a SVP, Strategy and Corporate Development at IDEX Corporation.
"This year's CHI Spring Luncheon is all about celebrating the power of women, and we are thrilled to have three exceptional honorees," said Dr. Dina Pahlajani, Cofounder and President of Children's Hope India.
For more information about Children's Hope India and to purchase tickets, please visit our website .

Medigene presents streamlined 6-day, high stemness TCR-T therapy production process

Retrieved on:

星期四, 四月 25, 2024

CTA, Synovial sarcoma, Safety, Cytokine, MD, Stomach, DP, Interferon, PD-L1, CHI, Patient, Neoplasm, CSP, DPS, CTAS, TCR, Ovarian cancer, Vaccine

Medigene tackles these challenges with a comprehensive approach, which starts with the development of a potential best-in-class, 3S (sensitive, specific, and safe) TCR.

Key Points:

Medigene tackles these challenges with a comprehensive approach, which starts with the development of a potential best-in-class, 3S (sensitive, specific, and safe) TCR.
This process is vital for producing effective, safe, and durable TCR-T therapies," stated Kirsty Crame, MD, VP Clinical Strategy & Development.
Medigene has developed a streamlined 6-day manufacturing process that focuses on the enrichment of CD8+ T cells whilst simultaneously maintaining a high degree of stemness.
Clinical indications for MDG1015 were primarily chosen based on the high unmet medical need, expression of the target antigen and/or PD-L1.

AM Best Downgrades and Withdraws Credit Ratings of Conifer Holdings, Inc. and Subsidiaries

Retrieved on:

星期四, 三月 14, 2024

Finance, Data Analytics, Professional Services, Other Professional Services, Insurance, ERM, ALL, News, CHI, Credit, AM Best, CIC, Good, Conifer, Risk management

Concurrently, AM Best has placed all of these Credit Ratings (ratings) under review with negative implications.

Key Points:

Concurrently, AM Best has placed all of these Credit Ratings (ratings) under review with negative implications.
At the same time, AM Best has withdrawn all of these ratings as the company has requested to no longer participate in AM Best’s interactive rating process.
For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings .
For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .

Alphawave Semi Demonstrates 3nm Silicon-Proven 24Gbps Universal Chiplet ExpressTM (UCIeTM) Subsystem for High-Performance AI Infrastructure

Retrieved on:

星期二, 三月 12, 2024

This new silicon-proven Universal Chiplet Interconnect Express (UCIeTM) subsystem expands Alphawave Semi’s portfolio and leadership in connectivity silicon.

Key Points:

This new silicon-proven Universal Chiplet Interconnect Express (UCIeTM) subsystem expands Alphawave Semi’s portfolio and leadership in connectivity silicon.
It paves the way for a robust, open chiplet ecosystem that accelerates connectivity and compute for high-performance AI systems.
An industry-first live demo of Alphawave Semi’s 24Gbps UCIe silicon platform on the TSMC 3nm process was recently unveiled at the Chiplet Summit in Santa Clara, CA.
View the full release here: https://www.businesswire.com/news/home/20240311461384/en/
Alphawave Semi 24Gbps UCIe 3nm silicon platform (Graphic: Business Wire)
Alphawave Semi’s 3nm UCIe complete PHY + Controller subsystem is capable of 24Gbps data rates, delivering high bandwidth density at extremely low power and low latency.

Leading Healthcare Strategist Jeff Moser Joins Compass One Healthcare

Retrieved on:

星期四, 二月 8, 2024

Managed Care, Hospitals, Health, Practice Management, Strategic planning, Economics, Psychology, Compass One, Texas Christian University, Senior, Hospital, Compass, Springfield College, Cardinal Health, CHI, Nursing

Jeff Moser, a leading healthcare strategist with over 30 years of experience, has joined Compass One Healthcare (Compass One) as the Senior Vice President of Partner Strategy.

Key Points:

Jeff Moser, a leading healthcare strategist with over 30 years of experience, has joined Compass One Healthcare (Compass One) as the Senior Vice President of Partner Strategy.
In his new role, Moser leads Compass One’s partner engagement strategy, focusing on identifying new opportunities, creating value, and growing existing relationships with hospitals and health systems.
“Jeff knows the key drivers of health system financial, operational, and clinical performance, and he is known for being a trusted advisor to healthcare C-Suite executives and critical decision-makers,” said Compass One chief executive officer Bobby Kutteh.
During his time at Sg2, Moser was a trusted advisor to Compass One on critical drivers of health system financial, operational, and clinical performance.

Tenstorrent Selects Blue Cheetah Chiplet Interconnect IP For Its AI and RISC-V Solutions

Retrieved on:

星期二, 二月 6, 2024

CHI, National Oceanography Centre, Southampton, AXI, ACE, Bow, OCP, PHY, UCIe

SUNNYVALE, Calif., Feb. 6, 2024 /PRNewswire/ -- Tenstorrent and Blue Cheetah Analog Design today announced that Tenstorrent has licensed Blue Cheetah's die-to-die interconnect IP for its AI and RISC-V chiplet solutions.

Key Points:

SUNNYVALE, Calif., Feb. 6, 2024 /PRNewswire/ -- Tenstorrent and Blue Cheetah Analog Design today announced that Tenstorrent has licensed Blue Cheetah's die-to-die interconnect IP for its AI and RISC-V chiplet solutions.
By selecting Blue Cheetah, Tenstorrent aims to accelerate its own as well as its customers' and partners' development of chiplet-based AI and RISC-V solutions.
Blue Cheetah currently provides its chiplet interconnect IP solutions in 4 nm, 5nm, 7nm, 12nm, and 16nm process technologies.
"Tenstorrent delivers highly customized, high-performance AI and RISC-V chiplet solutions tailored to specific workloads and applications," said Elad Alon, CEO of Blue Cheetah.

Lumosa Therapeutics and CHI Memorial announce new study for acute stroke

Retrieved on:

星期五, 二月 2, 2024

CHI, CCNR, Stroke, BRIGHT, Patient, Tissue plasminogen activator, Brain, Therapy, Hope, Doctor of Philosophy, U.S. FDA, Pharmaceutical industry

TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke.

Key Points:

TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke.
Lumosa and CHI Memorial aim to redefine what is possible in preventing stroke disability and impairment.
In December 2023, CHI Memorial achieved a significant milestone by enrolling the first U.S. patient in the Lumosa 203, double-blinded stroke study.
Lumosa and CHI Memorial are committed to advancing medical innovation and improving the lives of stroke patients worldwide.

Lumosa Therapeutics and CHI Memorial announce new study for acute stroke

Retrieved on:

星期五, 二月 2, 2024

CHI, CCNR, Stroke, BRIGHT, Patient, Tissue plasminogen activator, Brain, Therapy, Hope, Doctor of Philosophy, U.S. FDA, Pharmaceutical industry

TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke.

Key Points:

TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke.
Lumosa and CHI Memorial aim to redefine what is possible in preventing stroke disability and impairment.
In December 2023, CHI Memorial achieved a significant milestone by enrolling the first U.S. patient in the Lumosa 203, double-blinded stroke study.
Lumosa and CHI Memorial are committed to advancing medical innovation and improving the lives of stroke patients worldwide.